366 related articles for article (PubMed ID: 31102185)
41. Effects of chronic expression of the HIV-induced protein, transactivator of transcription, on circadian activity rhythms in mice, with or without morphine.
Duncan MJ; Bruce-Keller AJ; Conner C; Knapp PE; Xu R; Nath A; Hauser KF
Am J Physiol Regul Integr Comp Physiol; 2008 Nov; 295(5):R1680-7. PubMed ID: 18784333
[TBL] [Abstract][Full Text] [Related]
42. Ligand-gated purinergic receptors regulate HIV-1 Tat and morphine related neurotoxicity in primary mouse striatal neuron-glia co-cultures.
Sorrell ME; Hauser KF
J Neuroimmune Pharmacol; 2014 Mar; 9(2):233-44. PubMed ID: 24158495
[TBL] [Abstract][Full Text] [Related]
43. Morphine Tolerance and Physical Dependence Are Altered in Conditional HIV-1 Tat Transgenic Mice.
Fitting S; Stevens DL; Khan FA; Scoggins KL; Enga RM; Beardsley PM; Knapp PE; Dewey WL; Hauser KF
J Pharmacol Exp Ther; 2016 Jan; 356(1):96-105. PubMed ID: 26542403
[TBL] [Abstract][Full Text] [Related]
44. HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.
Imaz A; Martinez-Picado J; Niubó J; Kashuba AD; Ferrer E; Ouchi D; Sykes C; Rozas N; Acerete L; Curto J; Vila A; Podzamczer D
J Infect Dis; 2016 Nov; 214(10):1512-1519. PubMed ID: 27578849
[TBL] [Abstract][Full Text] [Related]
45. In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.
Cisternino S; Rousselle C; Debray M; Scherrmann JM
Pharm Res; 2004 Aug; 21(8):1382-9. PubMed ID: 15359572
[TBL] [Abstract][Full Text] [Related]
46. HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9.
Xu R; Feng X; Xie X; Zhang J; Wu D; Xu L
Brain Res; 2012 Feb; 1436():13-9. PubMed ID: 22197032
[TBL] [Abstract][Full Text] [Related]
47. Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
Allavena C; Volteau C; André-Garnier E; Guimard T; Hall N; Khatchatourian L; Morrier M; Billaud E; Rodallec A; Reliquet V; Jovelin T; Le Guen L; Perré P; Grégoire M; Raffi F
Med Mal Infect; 2019 Oct; 49(7):505-510. PubMed ID: 30583867
[TBL] [Abstract][Full Text] [Related]
48. Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice.
Mediouni S; Jablonski J; Paris JJ; Clementz MA; Thenin-Houssier S; McLaughlin JP; Valente ST
Curr HIV Res; 2015; 13(1):64-79. PubMed ID: 25613133
[TBL] [Abstract][Full Text] [Related]
49. Excess soluble CD40L contributes to blood brain barrier permeability in vivo: implications for HIV-associated neurocognitive disorders.
Davidson DC; Hirschman MP; Sun A; Singh MV; Kasischke K; Maggirwar SB
PLoS One; 2012; 7(12):e51793. PubMed ID: 23251626
[TBL] [Abstract][Full Text] [Related]
50. Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection.
Med Lett Drugs Ther; 2019 Aug; 61(1579):134-136. PubMed ID: 31581158
[No Abstract] [Full Text] [Related]
51. Differential effects of Tat proteins derived from HIV-1 subtypes B and recombinant CRF02_AG on human brain microvascular endothelial cells: implications for blood-brain barrier dysfunction.
Woollard SM; Bhargavan B; Yu F; Kanmogne GD
J Cereb Blood Flow Metab; 2014 Jun; 34(6):1047-59. PubMed ID: 24667918
[TBL] [Abstract][Full Text] [Related]
52. Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice.
Schier CJ; Marks WD; Paris JJ; Barbour AJ; McLane VD; Maragos WF; McQuiston AR; Knapp PE; Hauser KF
J Neurosci; 2017 Jun; 37(23):5758-5769. PubMed ID: 28473642
[TBL] [Abstract][Full Text] [Related]
53. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.
Walmsley S; Baumgarten A; Berenguer J; Felizarta F; Florence E; Khuong-Josses MA; Kilby JM; Lutz T; Podzamczer D; Portilla J; Roth N; Wong D; Granier C; Wynne B; Pappa K
J Acquir Immune Defic Syndr; 2015 Dec; 70(5):515-9. PubMed ID: 26262777
[TBL] [Abstract][Full Text] [Related]
54. Depressive-like Behavior Is Accompanied by Prefrontal Cortical Innate Immune Fatigue and Dendritic Spine Losses after HIV-1 Tat and Morphine Exposure.
Nass SR; Hahn YK; Ohene-Nyako M; McLane VD; Damaj MI; Thacker LR; Knapp PE; Hauser KF
Viruses; 2023 Feb; 15(3):. PubMed ID: 36992299
[TBL] [Abstract][Full Text] [Related]
55. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
56. P-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenac.
Sanchez-Covarrubias L; Slosky LM; Thompson BJ; Zhang Y; Laracuente ML; DeMarco KM; Ronaldson PT; Davis TP
PLoS One; 2014; 9(2):e88516. PubMed ID: 24520393
[TBL] [Abstract][Full Text] [Related]
57. Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers.
Namanja HA; Emmert D; Davis DA; Campos C; Miller DS; Hrycyna CA; Chmielewski J
J Am Chem Soc; 2012 Feb; 134(6):2976-80. PubMed ID: 21866921
[TBL] [Abstract][Full Text] [Related]
58. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
Wang LH; Chittick GE; McDowell JA
Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227
[TBL] [Abstract][Full Text] [Related]
59. Decreased glial and synaptic glutamate uptake in the striatum of HIV-1 gp120 transgenic mice.
Melendez RI; Roman C; Capo-Velez CM; Lasalde-Dominicci JA
J Neurovirol; 2016 Jun; 22(3):358-65. PubMed ID: 26567011
[TBL] [Abstract][Full Text] [Related]
60. HIV and viral protein effects on the blood brain barrier.
McRae M
Tissue Barriers; 2016; 4(1):e1143543. PubMed ID: 27141423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
